Botulinum toxin companies
Botulinum toxin products may involve different companies at different stages of their development and sale. The developer, physical manufacturer, regulatory holder, current owner, and commercialization partner are not always the same company, and these roles can differ by market.
Brand To Company Map
Section titled “Brand To Company Map”| Brand or product family | Companies | Roles |
|---|---|---|
| Botox / Botox Cosmetic | AbbVie / Allergan | Allergan built the Botox franchise; AbbVie became its parent company through the 2020 Allergan acquisition. |
| Dysport | Ipsen and Galderma | Ipsen is tied to the product’s origin and therapeutic business; Galderma commercializes aesthetic Dysport-family products in licensed territories. |
| Xeomin | Merz Pharma | Merz is the company behind the incobotulinumtoxinA product. |
| Jeuveau / Nabota | Daewoong Pharmaceutical and Evolus | Daewoong manufactures the product; Evolus commercializes Jeuveau in the United States and Nuceiva in selected international markets. |
| Letybo / Botulax | Hugel | Hugel links the Korea-origin product family to the Letybo name used in the United States and other markets. |
| Relfydess | Galderma | Galderma developed Relfydess, a role separate from its licensed commercialization of Dysport-family products. |
| Liztox / Hutox | Huons BioPharma | Huons BioPharma is associated with these Korea-origin toxin product names. |
| Re N Tox | PharmaResearchBio | PharmaResearchBio manufactures and exports Re N Tox and operates within the wider PharmaResearch group. |
| Daxxify | Revance / Crown Laboratories | Revance developed Daxxify; Crown Laboratories became the parent company after acquiring Revance in 2025. |
| Myobloc / Neurobloc | Supernus Pharmaceuticals | Supernus holds the current U.S. commercial portfolio relationship after acquiring the US WorldMeds CNS portfolio. |
| Boey | AbbVie / Allergan | The type E product sits within the AbbVie / Allergan toxin portfolio but remains separate from the type A Botox franchise. |
Company Directory
Section titled “Company Directory”| Company | Base | Ownership or listing | Toxin relationship |
|---|---|---|---|
| AbbVie / Allergan | United States | Public; NYSE: ABBV | Current parent company and legacy franchise history for Botox, Botox Cosmetic, and Boey. |
| Ipsen | France | Public; Euronext Paris | Product-origin and therapeutic company for Dysport. |
| Galderma | Switzerland | Public; SIX: GALD | Aesthetic commercialization partner for Dysport in licensed territories and developer of Relfydess. |
| Merz Pharma | Germany | Private | Company behind Xeomin. |
| Daewoong Pharmaceutical | South Korea | Public; KRX: 069620 | Manufacturer of the Nabota / Jeuveau product family. |
| Evolus | United States | Public; Nasdaq: EOLS | Commercialization company for Jeuveau in the United States and Nuceiva in selected international markets. |
| Hugel | South Korea | Public; KOSDAQ: 145020 | Company behind the Botulax / Letybo product family. |
| Medytox | South Korea | Public; KOSDAQ: 086900 | Developer and manufacturer associated with several type A toxin product lines. |
| Jetema | South Korea | Public; KOSDAQ: 216080 | Medical-aesthetics company with a botulinum toxin type A business. |
| Huons BioPharma | South Korea | Huons group company | Biopharmaceutical company associated with Liztox and Hutox. |
| Chong Kun Dang Pharm | South Korea | Public; KRX: 185750 | Pharmaceutical company associated with WonderTox. |
| Lanzhou Institute of Biological Products | China | State-owned biological-products company | Manufacturer associated with the history of Lantox, BTXA, and Hengli product names. |
| Medyceles | India | Regional manufacturer | India-associated manufacturer with limited public English-language documentation. |
| Gufic Biosciences | India | Public company | Manufacturer with a documented Navsari toxin facility, Prime Bio collaboration, and Zarbot product reference. |
| PharmaResearchBio | South Korea | PharmaResearch subsidiary | Manufacturer and exporter of Re N Tox. |
| Revance / Crown Laboratories | United States | Private | Daxxify developer and current parent-company relationship following Crown’s 2025 acquisition of Revance. |
| Supernus Pharmaceuticals | United States | Public; Nasdaq: SUPN | Current U.S. commercial portfolio company for the type B product Myobloc. |
How Company Roles Differ
Section titled “How Company Roles Differ”| Role | What it establishes | Examples |
|---|---|---|
| Product developer | The company responsible for bringing a product or formulation through development. | Revance developed Daxxify; Galderma developed Relfydess. |
| Physical manufacturer | The company that produces the product. This may differ from the company selling it in a particular market. | Daewoong manufactures Nabota / Jeuveau; PharmaResearchBio manufactures Re N Tox. |
| Commercialization partner | The company responsible for marketing or distributing a product under licensed rights in specified territories. | Evolus commercializes Jeuveau and Nuceiva; Galderma commercializes aesthetic Dysport-family products in licensed territories. |
| Current owner or parent company | The company that owns a business or product portfolio following an acquisition. | AbbVie acquired Allergan in 2020; Crown Laboratories acquired Revance in 2025. |
| Legacy company | A former owner or company name that remains important in labels, historical records, or product literature. | Allergan remains central to Botox history even though AbbVie is the current parent company. |
Regional Names And Market Boundaries
Section titled “Regional Names And Market Boundaries”One product family may appear under different names across markets. Daewoong’s product is sold as Nabota, Jeuveau, or Nuceiva depending on the market and commercial arrangement; Hugel’s product family connects the Botulax and Letybo names. Myobloc and Neurobloc are regional names associated with a type B product.
Shared manufacturer or product-family history does not create one global label. Approval status, indications, vial presentations, distribution rights, and product information must be checked for the specific product and market.
Comparison Limits
Section titled “Comparison Limits”Company relationships describe market structure, not clinical ranking. Products linked to the same company, country, toxin type, or commercial partner are not necessarily interchangeable or unit-equivalent and should not be assumed to have the same formulation, approvals, safety profile, strength, or duration.
Brands provides product-level entries for Botox, Dysport, Xeomin, Jeuveau, Daxxify, Letybo, and Myobloc / Neurobloc. Botulinum toxin covers the wider medicine family, while type A vs type B separates serotype biology from brand and company identity.